Creative Planning Sells 16,761 Shares of Genmab A/S (NASDAQ:GMAB)

Creative Planning trimmed its holdings in Genmab A/S (NASDAQ:GMAB) by 45.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,069 shares of the company’s stock after selling 16,761 shares during the quarter. Creative Planning’s holdings in Genmab A/S were worth $504,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. DDD Partners LLC purchased a new stake in shares of Genmab A/S in the second quarter worth approximately $8,860,000. Capital International Investors grew its holdings in shares of Genmab A/S by 7.8% in the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after acquiring an additional 315,355 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after acquiring an additional 145,689 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after acquiring an additional 103,859 shares in the last quarter. Finally, Ingalls & Snyder LLC grew its holdings in shares of Genmab A/S by 29.3% in the second quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock valued at $5,772,000 after acquiring an additional 52,117 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Trading Up 0.6 %

NASDAQ GMAB opened at $23.66 on Tuesday. Genmab A/S has a 1-year low of $23.24 and a 1-year high of $33.45. The stock has a 50-day moving average of $26.03 and a 200-day moving average of $27.26. The firm has a market cap of $15.65 billion, a PE ratio of 19.72, a price-to-earnings-growth ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The business had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. As a group, equities research analysts forecast that Genmab A/S will post 1.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on GMAB. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Friday, September 20th. Truist Financial lowered their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, September 9th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.